Oral presentation
Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD
Chairs
P. Kirkham
Wolverhampton (West Midlands)
(United Kingdom)
08:30
TRPV4 and activation of airway sensory nerves: The role of ATP
S. Bonvini(London, United Kingdom)
COI
1
08:45
Activation of TRPV4 triggers ATP release and mast cell dependent contraction of airway smooth muscle (ASM)
S. Bonvini(London, United Kingdom)
COI
2
09:00
Beneficial effects of menthol are mediated via a TRPM8-independent mechanism
S. Maher(London, United Kingdom)
COI
3
09:15
Effectiveness of 15-deoxy-delta-12-14-prostaglandin J2 on established asthma pathological changes triggered by house dust mite in mice
D. Coutinho(Rio De Janeiro (RJ), Brazil)
COI
4
09:30
Discovery of PRS-060, an inhalable CD123/IL4Ra/TH2 blocking anti-asthmatic anticalin protein re-engineered from endogenous lipocalin-1
G. Anderson(Parkville (VIC), Australia)
COI
5
09:45
MUC4 overexpression correlates corticoid resistance in chronic rhinosinusitis with nasal polyps
S. Contreras(Valencia, Spain)
COI
6
10:00
CompEx – A novel composite asthma exacerbation endpoint
A. Fuhlbrigge(Boston, United States)
COI
7
10:15
Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS)
D. Price(Singapore, Singapore)
COI
8
. . .
